Drug intelligence / Profile preview

LGX 242

Development stage: Preclinical
Lead developer: Logix Biosciences
Modality: Small Molecules
Administration: Intranasal

Overview

LGX 242 is a novel drug candidate derived from medical-grade manuka honey, currently under development by Logix Biosciences in collaboration with the Mayo Clinic. The therapeutic is designed to address precision allergy relief, mutating infectious diseases, and antimicrobial resistance. By leveraging Logix's biopharmaceutical development expertise and Mayo Clinic's research infrastructure, the program aims to develop targeted therapies that utilize the complex bioactive components of manuka honey. As of 2024, the candidate is in preclinical development, with clinical studies anticipated to begin pending regulatory approval and funding.

Other names: LGX 242LGX242LGX-242

Beyond the preview

Go deeper on LGX 242.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LGX 242.

Explore the full profile